SCHEMBL1304354

SCHEMBL1304354

CC(=O)N1C(=O)C(=Cc2ccc(C=C3C(=O)Nc4ccc(C(=O)O)cc43)o2)c2ccccc21.[NaH]

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.52
TLK2 Q86UE8 4/20 0.48
PDPK1 O15530 1/20 0.48
JAK3 P52333 1/20 0.48
PTPN1 P18031 5/20 0.47
PTPN2 P17706 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 2/20 0.44
POLB P06746 2/20 0.44
DYRK1A Q13627 1/20 0.44
LMNA P02545 1/20 0.44
THRB P10828 1/20 0.44
ALOX12 P18054 1/20 0.44
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KDR P35968 2/20 0.43
CDK2 P24941 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1304351 1.00 PIM1 (0.52) PIM1TLK2PDPK1JAK3PTPN1
SCHEMBL3130082 0.99 PIM1 (0.52) PIM1TLK2PDPK1JAK3PTPN1
SCHEMBL3130088 0.99 PIM1 (0.52) PIM1TLK2PDPK1JAK3PTPN1
SCHEMBL1304861 0.93 PIM1 (0.52) PIM1TLK2PDPK1JAK3PTPN1
SCHEMBL1304858 0.93 PIM1 (0.52) PIM1TLK2PDPK1JAK3PTPN1
SCHEMBL1304433 0.92 PIM1 (0.52) PIM1TLK2PDPK1JAK3PTPN1
SCHEMBL1304434 0.92 PIM1 (0.52) PIM1TLK2PDPK1JAK3PTPN1
SCHEMBL1304353 0.90 PTPN1 (0.46) PIM1TLK2PTPN1PTPN2MEN1
SCHEMBL1304522 0.87 ALDH1A1 (0.58) PIM1PTPN1PTPN2MEN1KMT2A
SCHEMBL1304521 0.87 ALDH1A1 (0.58) PIM1PTPN1PTPN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053461-B2 Oxindole derivative THERAVALUES CORPORATION (JP) 2011-11-08 US disclosed
US-20100076049-A1 NOVEL OXINDOLE DERIVATIVE THERAVALUES CORPORATION (JP) 2010-03-25 US disclosed
EP-2130829-A1 NOVEL HYDROXYINDOLE DERIVATIVE Theravalues Corporation (JP) 2009-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076049-A1 NOVEL OXINDOLE DERIVATIVE CYP2C9, HDAC10, SIGMAR1 PIM1 4561/4885TLK2 4211/4885PDPK1 4317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.